Pharming Group
PHAR
Company Profile
Business description
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Contact
Darwinweg 24
LeidenZH2333 CR
NLDT: +31 715247400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
409
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,879.30 | 12.90 | -0.15% |
| CAC 40 | 8,086.00 | 31.42 | -0.39% |
| DAX 40 | 24,606.77 | 130.47 | -0.53% |
| Dow JONES (US) | 50,285.66 | 276.31 | 0.55% |
| FTSE 100 | 10,443.47 | 11.13 | 0.11% |
| HKSE | 25,596.87 | 210.35 | 0.83% |
| NASDAQ | 26,293.10 | 22.74 | 0.09% |
| Nikkei 225 | 62,820.09 | 1,135.95 | 1.84% |
| NZX 50 Index | 12,923.14 | 45.07 | 0.35% |
| S&P 500 | 7,445.72 | 12.75 | 0.17% |
| S&P/ASX 200 | 8,655.90 | 16.20 | -0.19% |
| SSE Composite Index | 4,096.17 | 18.90 | 0.46% |